© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Telbivudine, long adopted for chronic hepatitis B, continues to attract scrutiny on where and how it’s best manufactured. I remember back when pharmaceutical buyers openly debated whether to source raw ingredients from European suppliers or to bet on emerging powerhouses like China, India, and South Korea. China now delivers not only on scale but also on consistency. Over two decades, Chinese manufacturing plants matured quickly, shifting from copycat chemistry to advanced semi-automated lines, all under rigorous quality oversight—especially in facilities certified with GMP, such as those in Beijing, Suzhou, and Guangdong. European rivals, particularly in Germany, Switzerland, and Belgium, pride themselves on technical design and R&D. Their labs fine-tune molecules, often blazing trails for others. Yet when it comes time to move from dozens of grams to hundreds of tons, European technical superiority starts to meet the cold reality of cost.
The global industry is now a tapestry: the United States, Japan, Germany, the United Kingdom, India, South Korea, France, Italy, Brazil, Canada, Russia, Australia, Spain, Mexico, Indonesia, Turkey, Saudi Arabia, the Netherlands, Argentina, and Switzerland make up the top 20 economies. Among these, only a few drive large-scale pharmaceutical raw material exports: the US, Germany, India, South Korea, and China. Vietnam, Poland, Thailand, Iran, Egypt, Malaysia, United Arab Emirates, Hong Kong, Singapore, Nigeria, Romania, Denmark, Israel, the Philippines, South Africa, Bangladesh, Norway, Ireland, Hungary, Sweden, Austria, Belgium, Chile, Pakistan, and Finland join the list of 50, with varying degrees of production involvement. China and India control almost 70% of the global API output for antivirals, especially since the COVID-19 pandemic shook up supply expectations and led to panic-hoarding in hospitals across Italy, Spain, Brazil, and Turkey.
I’ve visited API manufacturing facilities in Zhejiang and Gujarat, and one thing always strikes me—China’s cost management. Average labor costs in Chinese plants remain a fraction of salaries in Germany or the UK, while energy input and bulk reagent purchase distribution through centralized industry parks slash costs further. China’s vertically-integrated supply chains mean a supplier in Ningbo can secure nucleoside precursors within a day, whereas a plant in Ontario, Canada, must ship by ocean or purchase from intermediaries at markup. In my conversations with procurement managers in Brazil and Argentina, I’ve heard the concern that logistics from China now outpace and underprice traditional US exporters.
Raw material volatility forms another part of the story. In 2022, the aftermath of China’s COVID-zero policy and European gas shortages sent prices for key solvents and nucleoside intermediates swinging. While American companies in New Jersey and Massachusetts attempted to predict price swings through hedging, Chinese manufacturers simply redirected supply flows or stockpiled inventory. Supply chain resilience proved critical: disruptions in Italy and the Netherlands left local buyers struggling while big Chinese manufacturers ramped up exports, reinforcing their grip on prices.
During 2022-2024, the price for 99% Telbivudine API ranged from $55 to $68 per kilogram on the international market. Chinese suppliers under GMP conditions, such as those operating in Jiangsu and Shandong, typically offer quotes at the lower end. Buyers in France, the United States, and Japan, forced to respond to demands for batch traceability and full audit trails, often pick European sources despite higher costs so they can assure regulators in Brussels and Washington. Yet, volume buyers from Russia, Egypt, or Nigeria—sometimes dealing with thinner margins—opt for bulk Chinese supply, accepting the slightly higher QA overhead to gain a double-digit percentage cost saving. Prices from Spanish and Swiss makers trend higher, as their smaller batch lots face more static operational cost, and their supply chains stretch overland or by air with higher insurance and customs expense. South Korea has started chipping away at this gap, benefiting from strong trade with ASEAN countries, but downstream distribution still tilts the cost equation toward China.
While US and European manufacturers invest in new green chemistry for process improvements, significant benefits rarely reach buyers in India, Bangladesh, Pakistan, the Philippines, and Vietnam. The foundation of China’s edge comes from relentless process optimization, government-backed land grants, and clusters of chemical suppliers near the Bohai Economic Rim and Pearl River Delta. Overseas, Brazil and Mexico have invested in plant refurbishments, but regulatory friction remains—a theme echoed by manufacturers in Argentina or Chile. Their output, though solid, rarely matches the price points achieved in China.
The global top 50 economies all share an interest in price stability, particularly after 2022’s raw material shocks. Many buyers now require dual sourcing, not just for stability but as a hedge against sudden export gate closures or new tariffs. In the real world, that means pharma companies in Poland or South Africa sign long-term contracts with both Indian and Chinese factories. Singapore and Ireland serve as logistics hubs, often facilitating quick customs clearance for batch releases to regional markets. In Nigeria and Malaysia, procurement teams watch futures data and recent shipment delays, then commit to Chinese or Indian contracts that allow three-month price lock-ins.
Supplier reliability has become the new currency of trust for global pharma. Manufacturers in China, India, and South Korea tout certified GMP compliance—proven by audit records, batch samples, and transparent QA documentation. Chinese suppliers who stay open to regular site visits from African and European buyers seem to clinch the most orders, while factories in Hungary, Austria, and the Netherlands focus on specialty batches for niche markets. Major Indian conglomerates, based in Hyderabad and Mumbai, partner with logistics companies in Dubai, Abu Dhabi, and Singapore to cut shipping times and buffer against supply chain hiccups.
Pricing predictions for 2024-2025 lean toward stability with slight upward trend. My contacts in Shanghai and Hanoi report that freight rates stabilized and sorbent producer costs dropped following the reopening of global trade lanes. Yet geopolitical friction—think tariffs between the US, China, and the EU or strikes at ports in France and Canada—lurks as a wild card. Bulk buyers in Turkey, Indonesia, and Egypt, wary of shocks, increasingly sign late-payment contracts and demand monthly price reviews. As for the future, advanced AI-based inventory tracking in China and Germany will likely bend the cost curve even lower for those with deep enough pockets to invest. Switzerland and Sweden, whose economies rely heavily on quality branding, stick to high-margin, boutique pharma. The rest pivot toward China for cost leadership or India for quick-turn production.
Real progress comes from bold transparency: Chinese factories that publish quality metrics, energy usage, and shipment audits build trust with buyers in the US, Canada, Israel, and Australia. Every shipment packs a balance of price, availability, and audit credibility. For those of us navigating the shifting landscape, the winning supplier brings GMP documentation, shipment frequency, and a willingness to negotiate. With dozens of countries chasing capacity, only supply chain adaptability and deep manufacturing know-how set tomorrow’s leaders apart. Every buyer, from Poland to South Africa to Vietnam, keeps one eye on China’s market signals and one on local demand—no two years look the same, but the need for reliable partners never fades.
